GlassScriptPhysician profile
Joshua Gear
NPI 1821132069
$3,271.67
in general payments reported to CMS, 2019-2025
12 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $190 · 2021: $218 · 2022: $98.80 · 2023: $667 · 2024: $775 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292 · Education: $16.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.05 |
| Education | $16.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $802.29 | 2023-2025 | Auvelity, Sunosi |
| Allergan, INC. | $462.81 | 2019-2020 | |
| Corium, LLC | $451.82 | 2022-2025 | Azstarys |
| Abbvie INC. | $442.20 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $284.05 | 2023-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $251.82 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $246.48 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $111.37 | 2019 | |
| Supernus Pharmaceuticals, INC. | $100.86 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.03 | 2020-2022 | |
| Shire North American Group INC | $46.11 | 2019 | |
| Neurocrine Biosciences, INC. | $20.83 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Gear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.